View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Sponsored by SCHOTT Pharmaceutical Systems

Two Ways to Minimize the Delamination Risk of Glass Containers

Free White Paper

Two Ways to Minimize the Delamination Risk of Glass Containers

By SCHOTT Pharmaceutical Systems

Two Ways to Minimize the Delamination Risk of Glass Containers

By SCHOTT Pharmaceutical Systems
Enter your details to receive the free paper:

The recent spike in market recalls for injectable drug products due to visible flaky particles associated with ‘glass delamination’ demonstrates the need to solve these problems. It is important for both drug product and container manufacturers to understand the underlying mechanisms, to test for the potential risk, and to control drug container interactions to provide patients with safe medicine.

The recalls span multiple types of drugs, buffers, containers, and age of product on the market, demonstrating that this is a multi-factorial root cause problem. The good news is that there are multiple commercial packaging solutions from various manufacturers available to solve this problem, along with the drug formulation changes that (theoretically) can be made. But due to the lack in response time of the ‘delamination’ appearance, it is urgent to have tools on hand which give a quick confirmation about potential risks of the chosen drug-container combination.

Download this article, first published in the January 2012 edition of the PDA Letter, to find out more.

 

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology